Mechanisms and implications of imatinib resistance mutations in BCR-ABL

Current Opinion in Hematology

Volumn 11, Issue 1, 2004, Pages 35-43

  Nardi, Valentina ^a   Azam, Mohammad ^a   Daley, George Q ^b  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

BCR ABL kinase; Drug resistance; Imatinib; Point mutations; STI 571; Target directed chemotherapy

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 2 MORPHOLINO 8 PHENYLCHROMONE; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ABELSON KINASE; ADENOSINE TRIPHOSPHATE; ALPHA INTERFERON; ANTIBIOTIC AGENT; ARSENIC TRIOXIDE; BCR ABL PROTEIN; BOSUTINIB; CGP 76030; CYTARABINE; FLAVOPIRIDOL; GELDANAMYCIN; IMATINIB; LONAFARNIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TIPIFARNIB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VORINOSTAT; WORTMANNIN;

AMINO ACID SUBSTITUTION; AUTOPHOSPHORYLATION; BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPETITIVE INHIBITION; DRUG BINDING; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FUSION GENE; GENE AMPLIFICATION; GENE CONTROL; GENE MUTATION; GENE STRUCTURE; HUMAN; LEUKEMIA REMISSION; NONHUMAN; ONCOGENE; PHENOTYPE; PHILADELPHIA CHROMOSOME POSITIVE CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GENES, ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; POINT MUTATION; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 0348140591     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200401000-00006     Document Type: Review

References (75)

1. Nowell PC: HD, A minute chromosome in human chronic granulocytic leukemia. Science 1960, 132:1497.
2. Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990, 247:824-830.
3. Schindler T, Bornmann W, Pellicena P, et al.: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000, 289:1938-1942.
4. Kantarjian H, Sawyers C, Hochhaus A, et al.: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002, 346:645-652.
5. O'Brien SG, Guilhot F, Larson RA, et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
6. Sawyers CL, Hochhaus A, Feldman E, et al.: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99:3530-3539.
7. Talpaz M, Silver RT, Druker BJ, et al.: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002, 99:1928-1937.
8. Gambacorti-Passerini C, le Coutre P, Zucchetti M, et al.: Binding of imatinib by alpha(1)-acid glycoprotein. Blood 2002, 100:367-368; author reply 368-369.
9. Gambacorti-Passerini C, Zucchetti M, Russo D, et al.: Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003, 9:625-632.
10. le Coutre P, Kreuzer KA, Na IK, et al.: Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571. Blood Cells Mol Dis 2002, 28:75-85.
11. Mahon FX, Belloc F, Lagarde V, et al.: MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003, 101:2368-2373.
12. Gorre ME, Mohammed M, Ellwood K, et al.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
13. Tipping AJ, Mahon FX, Zafirides G, et al.: Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs. Leukemia 2002, 16:2349-2357.
14. Ben-Neriah Y, Bernards A, Paskind M, et al.: Alternative 5′ exons in c-abl mRNA. Cell 1986, 44:577-586.
15. Pluk H, Dorey K, Superti-Furga G: Autoinhibition of c-Abl. Cell 2002, 108:247-259.
16. Mayer BJ, Baltimore D: Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the AbI tyrosine kinase. Mol Cell Biol 1994, 14:2883-2894.
17. Barila D, Superti-Furga G: An intramolecular SH3-domain interaction regulates c-Abl activity. Nat Genet 1998, 18:280-282.
18. Harrison SC: Variation on an Src-like theme. Cell 2003, 112:737-740. This is an excellent, short, and yet comprehensive minireview about the "switch-clamp-latch" mechanism shared by SRC and ABL, and its implications for rationalizing imatinib resistance.
19. Van Etten RA: Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell Biol 1999, 9:179-186.
20. Nagar B, Hantschel O, Young MA, et al.: Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 2003, 112:859-871. In this paper the authors present the crystal structure of the inactive and assembled form of c-Abl 1b in comparison with c-Src and reveal an important role for an N-terminal myristoyl group in the autoinhibitory mechanisms.
21. Hantschel O, Nagar B, Guettler S, et al.: A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 2003, 112:845-857. The authors discuss the regulation of c-Abl 1b, and report the surprising role of the myristoyl moiety in mediating a conformation switch in the C lobe of the kinase that directly regulates the SH2-kinase domain contacts. They also demonstrate a direct kinase-activating effect of phosphotyrosine ligands.
22. Druker BJ, Tamura S, Buchdunger E, et al.: Effects of a selective inhibitor of the AbI tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
23. Nagar B, Bornmann WG, Pellicena P, et al.: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002, 62:4236-4243. In this report the authors describe the crystal structures of BCR-ABL in complex with imatinib or a structurally distinct pyridopyrimidine compound, which in stark contrast to imatinib binds to a form of ABL in which the activation loop can adopt the active or "on" state.
24. Shah NP, Nicoll JM, Nagar B, et al.: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002, 2:117-125. The authors detected a high frequency of mutations - as well as six novel variants - in CML patients, who relapsed after a hematologic response to imatinib. This is the first report describing cases of polyclonal resistance and of mutations preexisting imatinib therapy.
25. Branford S, Rudzki Z, Walsh S, et al.: High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002, 99:3472-3475.
26. Gambacorti-Passerini CB, Gunby RH, Piazza R, et al.: Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003, 4:75-85. This is a very detailed and comprehensive review of the different mechanisms of resistance to imatinib therapy. It contains an extensive structural consideration of different AbI mutations.
27. Barthe C, Cony-Makhoul P, Melo JV, et al.: Roots of clinical resistance to STI-571 cancer therapy. Science 2001, 293:2163.
28. Hochhaus A, Kreil S, Corbin A, et al.: Roots of clinical resistance to STI-571 cancer therapy. Science 2001, 293:2163.
29. Roumiantsev S, Shah NP, Gorre ME, et al.: Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the AbI kinase domain P-loop. Proc Natl Acad Sci U S A 2002, 99:10700-10705. The authors described a new mutation in the p-loop of BCR-ABL conferring an intermediate resistance to imatinib therapy, and suggest it could be linked to disease progression.
30. von Bubnoff N, Schneller F, Peschel C, et al.: BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002, 359:487-491.
31. Azam M, Latek RR, Daley GQ: Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003, 112:831-843. This paper describes an in vitro screen of randomly mutagenized BCR-ABL which detected virtually all clinically problematic mutations and numerous novel ones. This paper links kinase activation to imatinib resistance, and suggests the hypothesis that mutations release residual autoinhibition in BCR-ABL, and favor autophosphorylation, which precludes imatinib binding.
32. Gonfloni S, Williams JC, Hattula K, et al.: The role of the linker between the SH2 domain and catalytic domain in the regulation and function of Src. EMBO J 1997, 16:7261-7271.
33. Brasher BB, Roumiantsev S, Van Etten RA: Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain. Oncogene 2001, 20:7744-7752.
34. Young MA, Gonfloni S, Superti-Furga G, et al.: Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Cell 2001, 105:115-126.
35. Van Etten RA: c-Abl regulation: a tail of two lipids. Curr Biol 2003, 13:R608-R610.
36. Smith KM, Yacobi R, Van Etten RA: Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell 2003, 12:27-37.
37. Branford S, Rudzki Z, Walsh S, et al.: Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003, 102:276-283. The authors found a significant correlation in CML patients between mutations and either a longer interval to initiation of imatinib therapy, or failure to achieve cytogenetic control of the disease. They describe p loop variants as a poor prognostic feature.
38. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al.: Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002, 100:1014-1018. In this brief report the authors use a very sensitive assay to demonstrate that mutations can preexist imatinib therapy in rare CML cells and that this number then increases throughout treatment.
39. Hirota S, Isozaki K, Moriyama Y, et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577-580.
40. Nakahara M, Isozaki K, Hirota S, et al.: A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology 1998, 115:1090-1095.
41. Ma Y, Zeng S, Metcalfe DD, et al.: The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002, 99:1741-1744.
42. Lux ML, Rubin BP, Biase TL, et al.: KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000, 156:791-795.
43. Akin C, Brockow K, D'Ambrosio C, et al.: Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003, 31:686-692.
44. Liao AT, Chien MB, Shenoy N, et al.: Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 2002, 100:585-593.
45. Gilliland DG, Griffin JD: The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100:1532-1542.
46. Schnittger S, Schoch C, Dugas M, et al.: Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002, 100:59-66.
47. Reilly JT: Receptor tyrosine kinases in normal and malignant haematopoiesis. Blood Rev 2003, 17:241-248.
48. Grundler R, Thiede C, Miething C, et al.: Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. Blood 2003, 102:646-651.
49. Hochhaus A: A further milestone towards comprehensive standardization of quantitative RT-PCR protocols for leukemic fusion gene transcripts has been reached. Leukemia 2003, 9:9.
50. Hughes TP, Kaeda J, Branford S, et al.: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349:1423-1432.
51. Hochhaus A, Weisser A, La Rosee P, et al.: Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia 2000, 14:998-1005.
52. Olavarria E, Kanfer E, Szydlo R, et al.: Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2001, 97:1560-1565.
53. Golas JM, Arndt K, Etienne C, et al.: SKI-606, a 4-anilino-3- quinolinecarbonitrile dual inhibitor of Src and AbI kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003, 63:375-381.
54. von Bubnoff N, Veach DR, Miller WT, et al.: Inhibition of wild-type and mutant bcr-abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer Res 2003, 63:6395-6404.
55. Warmuth M, Simon N, Mitina O, et al.: Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood 2003, 101:664-672.
56. Wisniewski D, Lambek CL, Liu C, et al.: Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res 2002, 62:4244-4255.
57. Huron DR, Gorre ME, Kraker AJ, et al.: A novel pyridopyrimidine inhibitor of Abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res 2003, 9:1267-1273.
58. Gorre ME, Ellwood-Yen K, Chiosis G, et al.: BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002, 100:3041-3044.
59. Nimmanapalli R, O'Bryan E, Bhalla K: Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 2001, 61:1799-1804.
60. Puccetti E, Guller S, Orleth A, et al.: BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Res 2000, 60:3409-3413.
61. Porosnicu M, Nimmanapalli R, Nguyen D, et al.: Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. Leukemia 2001, 15:772-778.
62. La Rosee P, Johnson K, O'Dwyer ME, et al.: In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp Hematol 2002, 30:729-737.
63. Yu C, Krystal G, Dent P, et al.: Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin Cancer Res 2002, 8:2976-2984.
64. Nimmanapalli R, Fuino L, Stobaugh C, et al.: Co-treatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells. Blood 2003, 101:3236-3239.
65. Yu C, Rahmani M, Almenara J, et al.: Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571 -sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells. Cancer Res 2003, 63:2118-2126.
66. Uno K, Inukai T, Kayagaki N, et al.: TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Blood 2003, 101:3658-3667.
67. Guilhot F, Gardembas M, Rousselot P, et al.: Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials. Semin Hematol 2003, 40:92-97.
68. O'Dwyer ME, La Rosee P, Nimmanapalli R, et al.: Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide. Semin Hematol 2002, 39:18-21.
69. O'Brien SG: Imatinib for chronic myeloid leukaemia: a NICE mess. Lancet 2001, 358:1902-1903.
70. Rosti G, Trabacchi E, Bassi S, et al.: Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Haematologica 2003, 88:256-259.
71. Klejman A, Rushen L, Morrione A, et al.: Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 2002, 21:5868-5876.
72. Yu C, Krystal G, Varticovksi L, et al.: Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 2002, 62:188-199.
73. Hoover RR, Mahon FX, Melo JV, et al.: Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 2002, 100:1068-1071.
74. Cortes J, Ault P, Koller C, et al.: Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003, 101:1692-1697.
75. Daley GQ: Towards combination target-directed chemotherapy for chronic myeloid leukemia: Role of farnesyl transferase inhibitors. Semin Hematol 2003, 40:11-14.